Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader.
对新型蛋白水解靶向嵌合雄激素受体降解剂 Bavdegalutamide (ARV-110) 进行临床前评价
期刊:Molecular Cancer Therapeutics
影响因子:5.5
doi:10.1158/1535-7163.MCT-23-0655
Snyder Lawrence B, Neklesa Taavi K, Willard Ryan R, Gordon Deborah A, Pizzano Jennifer, Vitale Nicholas, Robling Kaitlynn, Dorso Madeline A, Moghrabi Walid, Landrette Sean, Gedrich Richard, Lee Sang Hyun, Taylor Ian C A, Houston John G
